Combining antihypertensive and antihyperlipidemic agents – optimizing cardiovascular risk factor management

References

• ZanchettiAThe hypertensive patient with multiple risk factors: is treatment really so difficult?Am J Hypertens199710223S229S9366277
   PubMed Web of Science ®Google Scholar
• GuDGuptaAMuntnerPPrevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia)Circulation200511265866516043645
   PubMed Web of Science ®Google Scholar
• AsmarRVolSPannierBBrisacAMTichetJEl HasnaouiAHigh blood pressure and associated cardiovascular risk factors in FranceJ Hypertens2001191727173211593091
   PubMed Web of Science ®Google Scholar
• KannelWBFifty years of Framingham Study contributions to understanding hypertensionJ Hum Hypertens200014839010723112
   PubMed Web of Science ®Google Scholar
• NeatonJDWentworthDSerum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research GroupArch Intern Med199215256641728930
   PubMed Web of Science ®Google Scholar
• ThomasFBeanKGuizeLQuentzelSArgyriadisPBenetosACombined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and womenEur Heart J20022352853511922642
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA20012852486249711368702
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA20032892560257212748199
   PubMed Web of Science ®Google Scholar
• GrahamIAtarDBorch-JohnsenKEuropean guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)Eur Heart J2007282375241417726041
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakA2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens2007251105118717563527
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupMajor outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA20022882981299712479763
   PubMed Web of Science ®Google Scholar
• SeverPSDahlöfBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet20033611149115812686036
   PubMed Web of Science ®Google Scholar
• WaldNJLawMRA strategy to reduce cardiovascular disease by more than 80%BMJ2003326141912829553
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet200436468569615325833
   PubMed Web of Science ®Google Scholar
• GædePVedelPLarsenNJensenGVParvingHHPedersenOMultifactorial intervention and cardiovascular disease in patients with type 2 diabetesN Engl J Med200334838339312556541
   PubMed Web of Science ®Google Scholar
• GædePLund-AndersenHParvingHHPedersenOEffect of a multifactorial intervention on mortality in type 2 diabetesN Engl J Med200835858059118256393
   PubMed Web of Science ®Google Scholar
• YusufSPaisPAfzalREffects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trialLancet20093731341135119339045
   PubMed Web of Science ®Google Scholar
• PatelAShahTShahGPreservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteersAm J Cardiovasc Drugs2010109510320334446
   PubMed Web of Science ®Google Scholar
• MalekzadehFMarshallTPourshamsAA pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factorsInt J Clin Pract2010641220122720653798
   PubMed Web of Science ®Google Scholar
• SleightPPouleurHZannadFBenefits, challenges, and registerability of the polypillEur Heart J2006271651165616603580
   PubMed Web of Science ®Google Scholar
• ZamoranoJErdineSLopezAPCardiovascular risk factor management – single-pill amlodipine/atorvastatin versus usual care in patients with hypertension and additional risk factors: the CRUCIAL trialCurr Med Res Opin20112782183321306285
   PubMed Web of Science ®Google Scholar
• BlankRHobbsFDZamoranoJGirerdXA single-pill combination of amlodipine besylate and atorvastatin calcium (update)Drugs Today (Barc)20074315717717380213
   PubMed Web of Science ®Google Scholar
• McKeageKSiddiquiMAAmlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemiaAm J Cardiovasc Drugs20088516718303938
   PubMed Web of Science ®Google Scholar
• CurranMPAmlodipine/atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular diseaseDrugs20107019121320108992
   PubMed Web of Science ®Google Scholar
• WhitworthJA2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertensionJ Hypertens2003211983199214597836
   PubMed Web of Science ®Google Scholar
• KotsevaKWoodDDe BackerGDe BacquerDPyöräläKKeilUEUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countriesEur J Cardiovasc Prev Rehabil20091612113719287307
   PubMed Web of Science ®Google Scholar
• YokokawaHGotoASanadaHWatanabeTYasumuraSLongitudinal community-based assessment of blood pressure control among Japanese hypertensive patients: Fukushima research of hypertension (FRESH)J Clin Hypertens201012166173
   Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet20043632022203115207952
   PubMed Web of Science ®Google Scholar
• DahlöfBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet200536689590616154016
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMLibbyPEffect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trialJAMA20042922217222515536108
   PubMed Web of Science ®Google Scholar
• BisognanoJMcLaughlinTRobertsCSIncremental effectiveness of amlodipine besylate in the treatment of hypertension with single and multiple medication regimensAm J Hypertens20041767668315323063
   PubMed Web of Science ®Google Scholar
• HariaMWagstaffAJAmlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular diseaseDrugs1995505605868521773
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med20053521425143515755765
   PubMed Web of Science ®Google Scholar
• MalhotraHSGoaKLAtorvastatin: an updated review of its pharmacological properties and use in dyslipidaemiaDrugs2001611835188111693468
   PubMed Web of Science ®Google Scholar
• Pfizer IncLipitor^® (atorvastatin calcium) [package insert]Pfizer IncNew York Available at: http://www.pfizer.com/files/products/uspi_lipitor.pdfAccessed February 24, 2011
   Google Scholar
• Pfizer IncNorvasc^® (amlodipine besylate) [package insert]Pfizer IncNew York Available at: http://media.pfizer.com/files/products/uspi_norvasc.pdfAccessed February 23, 2011
   Google Scholar
• Pfizer IncCaduet^® (amlodipine besylate/atorvastatin calcium) [package insert]Pfizer IncNew York Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=531Accessed February 24, 2011
   Google Scholar
• BlankRA single-pill combination of amlodipine besylate and atorvastatin calciumDrugs Today (Barc)20064215717516628258
   PubMed Web of Science ®Google Scholar
• ChungMCalcagniAGluePBramsonCBioavailability of amlodipine besylate/atorvastatin calcium combination tabletJ Clin Pharmacol2006461030103716920898
   PubMed Web of Science ®Google Scholar
• ChungMCalcagniAGluePBramsonCEffect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tabletJ Clin Pharmacol2006461212121616988211
   PubMed Web of Science ®Google Scholar
• MesserliFHBakrisGLFerreraDEff icacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trialJ Clin Hypertens20068571581
   Google Scholar
• PrestonRAHarveyPHerfertOA randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the Respond trialJ Clin Pharmacol2007471555156918048574
   PubMed Web of Science ®Google Scholar
• SeverPSDahlöfBPoulterNRPotential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes TrialEur Heart J2006272982298817145722
   PubMed Web of Science ®Google Scholar
• MasonRPKubantRHeebaGSynergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunctionPharm Res2008251798180618087679
   PubMed Web of Science ®Google Scholar
• CohnJNWilsonDJNeutelJCoadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemiaAm J Hypertens20092213714419057518
   PubMed Web of Science ®Google Scholar
• MerikleEPEvansCFeldmanRDPatient satisfaction with a single-pill treatment of hypertension and dyslipidemiaCirculation2007115e589 [Abstract]
   Web of Science ®Google Scholar
• PackerMO’ConnorCMGhaliJKEffect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study GroupN Engl J Med1996335110711148813041
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMKasteleinJJKostisJBGretenHSafety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study)Am J Cardiol200710074775217719314
   PubMed Web of Science ®Google Scholar
• NewmanCTsaiJSzarekMLuoDGibsonEComparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patientsAm J Cardiol200697616716377285
   PubMed Web of Science ®Google Scholar
• AmarencoPBogousslavskyJCallahanA3rdHigh-dose atorvastatin after stroke or transient ischemic attackN Engl J Med200635554955916899775
   PubMed Web of Science ®Google Scholar
• BlankRLasalleJReevesRMaroniJTarasenkoLSunFSingle-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the Amlodipine/Atorvastatin Gemini Study)J Clin Hypertens (Greenwich)2005726427315886529
   PubMedGoogle Scholar
• ErdineSRoYMTseHFSingle-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study)J Hum Hypertens20092319621018800143
   PubMed Web of Science ®Google Scholar
• HobbsFDGensiniGManciniGBCan combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)Int J Cardiol200611024225016338012
   PubMed Web of Science ®Google Scholar
• FlackJMVictorRWatsonKImproved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trialMayo Clin Proc200883354518174006
   PubMed Web of Science ®Google Scholar
• FerdinandKCFlackJMSaundersEAmlodipine/atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitusJ Clin Hypertens (Greenwich)20091158559319817942
   PubMed Web of Science ®Google Scholar
• HobbsFDRGensiniGManciniGBJInternational open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programmeEur J Cardiovasc Prev Rehabil20091647248019407658
   PubMed Web of Science ®Google Scholar
• FlackJMFeldmanRDHobbsFDRReduction in blood pressure and low-density lipoprotein cholesterol when single-pill amlodipine/atorvastatin is used as a first line or add-on treatmentPresented at the 2nd International Conference on Fixed Combination in the Treatment of Hypertension and Dyslipidemia2009Valencia, Spain
   Google Scholar
• FeldmanRDFlackJMHobbsFDRA comparison of blood pressure and low-density lipoprotein cholesterol reduction after treatment with single-pill amlodipine/atorvastatin in elderly (>75 years) and younger (<75 years) patients: results of a pooled analysis of 5559 patientsPresented at The 2nd International Conference on Fixed Combination in the Treatment of Hypertension and Dyslipidemia2009Valencia, Spain
   Google Scholar
• HobbsRFeldmanRFlackJA comparison of blood pressure and low-density lipoprotein cholesterol reduction after treatment with single-pill amlodipine/atorvastatin in younger (<65 years) and older (≥65 years) men and women: Results of a pooled analysis of 5559 patientsPresented at The 2nd International Conference on Fixed Combination in the Treatment of Hypertension and Dyslipidemia2009Valencia, Spain2009
   Google Scholar
• NeutelJMBestermannWHDyessEMThe use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter studyJ Clin Hypertens (Greenwich)200911223019125855
   PubMed Web of Science ®Google Scholar
• GrimmRMalikMYunisCSutradharSKursunASimultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trialVasc Health Risk Manag2010626127120479948
   PubMedGoogle Scholar
• WilsonPWD’AgostinoRBLevyDBelangerAMSilbershatzHKannelWBPrediction of coronary heart disease using risk factor categoriesCirculation199897183718479603539
   PubMed Web of Science ®Google Scholar
• ConroyRMPyöräläKFitzgeraldAPEstimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectEur Heart J200324987100312788299
   PubMed Web of Science ®Google Scholar
• D’AgostinoRBSrVasanRSPencinaMJGeneral cardiovascular risk profile for use in primary care. The Framingham Heart StudyCirculation200811774375318212285
   PubMed Web of Science ®Google Scholar
• WolfPAD’AgostinoRBBelangerAJKannelWBProbability of stroke: a risk profile from the Framingham StudyStroke1991223123182003301
   PubMed Web of Science ®Google Scholar
• ZamoranoJErdineSLopez PaviaASingle-pill amlodipine/atorvastatin versus usual care for cardiovascular risk factor management in patients with diabetes, hypertension and additional risk factors – a CRUCIAL trial subanalysis2010Presented at the 23rd International Society of Hypertension2010Vancouver, BC
   Google Scholar
• ZamoranoJErdineSLopez PaviaASingle-pill amlodipine/atorvastatin versus usual care for cardiovascular risk factor management in patients aged 65 years or more with hypertension and additional risk factors—a CRUCIAL trial subanalysis 2010Presented at the 23rd International Society of Hypertension2010Vancouver, BC
   Google Scholar
• ChoEJKimJHSutradharSReduction in cardiovascular risk using proactive multifactorial intervention is consistent regardless of ethnicity in Asian patients: Sub-analysis of the CRUCIAL TrialThe 43rd Annual Scientific Meeting of the Japan Atherosclerosis Society2011Sapporo, Japan
   Google Scholar
• Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative populationCirc J2006701249125516998254
   PubMed Web of Science ®Google Scholar
• KimJHChoEJSutradharSCardiovascular risk reduction in Pacific-Asian patients using a multifactorial intervention as assessed by using the NIPPON DATA80, SCORE and Framingham equations: CRUCIAL Trial sub-analysisThe 43rd Annual Scientific Meeting of the Japan Atherosclerosis Society2011Sapporo, Japan
   Google Scholar
• LindgrenPBuxtonMKahanTThe lifetime cost-effectiveness of amlodipine-based therapy + atorvastatin compared to atenolol + atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: Results from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)Pharmacoeconomics20092722123019354342
   PubMed Web of Science ®Google Scholar
• BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: a meta-analysisAm J Med200712071371917679131
   PubMed Web of Science ®Google Scholar
• HoPMBrysonCLRumsfeldJSMedication adherence: its importance in cardiovascular outcomesCirculation20091193028303519528344
   PubMed Web of Science ®Google Scholar
• ChapmanRHYeawJRobertsCSAssociation between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrolleesBMC Cardiovasc Disord2010102920565779
   PubMed Web of Science ®Google Scholar
• HoPMMagidDJShetterlySMMedication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery diseaseAm Heart J200815577277918371492
   PubMed Web of Science ®Google Scholar
• HoPMSpertusJAMasoudiFAImpact of medication therapy discontinuation on mortality after myocardial infarctionArch Intern Med20061661842184717000940
   PubMed Web of Science ®Google Scholar
• HoPMMagidDJShetterlySMImportance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary diseaseArch Intern Med200816827127618268167
   PubMed Web of Science ®Google Scholar
• CherrySBBennerJSHusseinMATangSSKNicholMBThe clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patientsValue Health20091248949718783393
   PubMed Web of Science ®Google Scholar
• LindgrenPErikssonJBuxtonMThe economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes TrialInt J Clin Pract2010641228123420500533
   PubMed Web of Science ®Google Scholar
• ChapmanRHBennerJSPetrillaAAPredictors of adherence with antihypertensive and lipid-lowering therapyArch Intern Med20051651147115215911728
   PubMed Web of Science ®Google Scholar
• BennerJSChapmanRHPetrillaAATangSSKRosenbergNSchwartzJSAssociation between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapyAm J Health Syst Pharm2009661471147719667004
   PubMed Web of Science ®Google Scholar
• AgarwalSTangSSKRosenbergNDoes synchronizing initiation of therapy affect adherence to concomitant use of antihypertensive and lipid-lowering therapy?Am J Ther20091611912619114872
   PubMed Web of Science ®Google Scholar
• PetrillaAABennerJSBattlemanDSTierceJCHazardEHEvidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medicationsInt J Clin Pract2005591441145116351677
   PubMed Web of Science ®Google Scholar
• ChapmanRHFerrufinoCPKowalSLClassiPRobertsCSThe cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugsInt J Clin Pract20106416918120089007
   PubMed Web of Science ®Google Scholar
• PatelBVLeslieRSThiebaudPAdherence with single-pill amlodipine/atorvastatin vs a two-pill regimenVasc Health Risk Manag2008467368118827917
   PubMedGoogle Scholar
• HusseinMAChapmanRHBennerJSDoes a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective studyAm J Cardiovasc Drugs20101019320220387911
   PubMed Web of Science ®Google Scholar
• ChapmanRHPelletierEMSmithPJRobertsCSCan adherence to antihypertensive therapy be used to promote adherence to statin therapy?Patient Prefer Adherence2009326527519936170
   PubMed Web of Science ®Google Scholar
• RobertsKJPhysician-patient relationships, patient satisfaction, and antiretroviral medication adherence among HIV-infected adults attending a public health clinicAIDS Patient Care STDS200216435011839218
   PubMed Web of Science ®Google Scholar
• WrothTHPathmanDEPrimary medication adherence in a rural population: the role of the patient-physician relationship and satisfaction with careJ Am Board Fam Med20061947848616951297
   PubMed Web of Science ®Google Scholar
• RenziCPicardiAAbeniDAssociation of dissatisfaction with care and psychiatric morbidity with poor treatment complianceArch Dermatol200213833734211902984
   PubMed Web of Science ®Google Scholar